Skip to main content
OpenTrials
Completed

NCT Number: NCT05614557

Impact of Silicon-based Formulations on Wound Healing of Laser-induced Microscopic Skin Lesions

Delayed wound healing is considered a health problem with devastating consequences for patients, healthcare systems, and societies. Over the past 20 years, many other groups, as well as ourselves, have evaluated various alternatives to improve wound healing. Despite this, the scientific evidence demonstrating the efficacy of recently developed treatments is often limited. Stratacel® and Stratamed® are two gels approved by Swissmedic and the FDA for use in improving wound healing. To this end, the efficacy of these formulations has been visually tested by a physician or by patients. Using the most advanced medical technologies (confocal microscopy and LCOCT), this study aims to investigate the effect of these formulations on the healing of human skin. For this research, a total of 20 volunteers will be included in this study. Volunteers will have up to 7 follow-up appointments over 21 days. Each appointment will last approximately 30 minutes and will be used to perform external measurements of skin healing. All volunteers will use the same formulations (Stratacel® and Stratamed®) with the only difference between volunteers being the anatomical area of application of the formulation. This will be determined by chance. The active participation of the participant is requested for the application of the formulations on the skin twice a day during the trial.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Wound Healing

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpitaux universitaires de Genève

Geneva, Switzerland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adult volunteers age ≥18 years to 50 years
  • Subjects must be willing and able to participate as required by the protocol.
  • Subjects must be willing and able to provide written informed consent.

Exclusion criteria

  • Evidence of any relevant skin or systemic disease (for example diabetes mellitus, cardiovascular disease, hypertension, chronic or acute skin disease) possibly affecting the wound healing of the test site.
  • Any skin alteration (for example tattoo or scar) on the test site.
  • Test sites with terminal hairs
  • Pregnancy or breastfeeding.
  • History of hypertrophic scars or keloid formation or a similar abnormal wound healing.
  • Intake of any drug which in the evaluation of the investigator may interfere with the interpretation of trial results or are known to cause clinically relevant interferences.
  • Body Mass Index (BMI) > 36 kg/m².
  • Have any other condition (including drug abuse, alcohol abuse, or psychiatric disorder) that, in the opinion of the investigator, precludes the patient from following and completing the protocol.

Treatment and study plan

Stratacel

Device

Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).

Stratamed

Device

Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).

Primary outcomes

  1. Measurement of erythema severity via erythema index with and without silicon-based formulations.

    Time frame: 21+-2 days maximum

    Erythema severity is measured using the erythema index (EI). EI will be evaluated by a Mexameter by means of duplicate measurements per skin area in arbitrary units.

Secondary outcomes

  1. Time needed for the scab to fall off

    Time frame: 21+-2 days maximum

    Time needed for the scab to fall off will be evaluated through the study of photo documentation conducted thorough the experiment. To obtain the best possible image of the microscopic treatment zones, a DermLite DL4 dermatoscope will be used. The dermatoscope is a non-invasive device, frequently used in dermatology, which allows a better observation of the skin surface by magnifying it.

  2. Volume of microscopic treatment zones (MTZs) and recovery time

    Time frame: 21+-2 days maximum

    Volume of the MTZs and time to recovery will be evaluated using confocal microscopy. Either by using RCM or LC-OCT (both non-invasive), a minimum of 3 MTZs per region will be evaluated. MTZs will also be evaluated following the classical protocol of biopsy fullowed by H&E staining.

Sponsors and collaborators

Lead sponsor

Stratpharma AG

Industry

Collaborators

  • University Hospital, Geneva

Registry information

Acronym: SPASM11

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Nov 14, 2022
Registry last updated
Sep 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.